The current stock price of MYOS is 1.01 null. In the past month the price decreased by -14.46%. In the past year, price decreased by -34.25%.
MYOS RENS Technology Inc. is a BioNutrition and BioTherapeutics company which focused on the discovery, development and commercialization of products which improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS RENS Technology Inc., formerly known as MYOS Corporation, is based in Cedar Knolls, New Jersey.
Myos Rens Tech
45 HORSEHILL ROAD SUITE 106
CEDAR KNOLLS NJ 07927
CEO: Joseph Mannello
Phone: 973-509-0444
MYOS RENS Technology Inc. is a BioNutrition and BioTherapeutics company which focused on the discovery, development and commercialization of products which improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS RENS Technology Inc., formerly known as MYOS Corporation, is based in Cedar Knolls, New Jersey.
The current stock price of MYOS is 1.01 null. The price decreased by -10.62% in the last trading session.
MYOS does not pay a dividend.
MYOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
MYOS stock is listed on the Nasdaq exchange.
ChartMill assigns a fundamental rating of 3 / 10 to MYOS. Both the profitability and financial health of MYOS have multiple concerns.
Over the last trailing twelve months MYOS reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 8.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -245.38% | ||
| ROA | -110.91% | ||
| ROE | N/A | ||
| Debt/Equity | 0.15 |